arrow-down arrow-left arrow-right check clock edit filter phone question-mark search submit-arrow

Medicines in development

 

Out of approximately 10.000 known diseases, only 5% have registered treatments available. Drug development aims to address this need for more treatments, but it can take more than 12 years for a medicine to be authorized and go to market. This leaves many doctors and their patients without access to treatment options that already show hopeful results during this period.

 

Early access or compassionate use programs are intended to help fill this gap, but in reality there are many hurdles to identify and access medicines in development making them practically inaccessible.

 

Our Challenge

 

myTomorrows is an independent, globally operating organization based in the Netherlands. We provide patients with unmet medical needs, and their doctors, information about treatment options worldwide and facilitate access to medicines in development.

 

Our goal is to ensure that patients and doctors don’t miss out on treatment options due to lack of information, understanding and administrative hurdles.

 

Up to date information

 

 

The world of medicines in development is vast and complicated: information is fragmented and written in highly specific medical language. It’s difficult for a patient to understand and very time consuming for a doctor to identify possible treatment options for unmet medical needs.

To make this easier for patients and doctors, we have built an extensive Knowledge Base with up-to-date information on medicines in development available around the world, clinical trials and scientific publications. We have created separate entry points for patients and doctors so that patients are not overwhelmed with medical jargon.

Patient and doctors in control

 

myTomorrows does not provide any form of diagnostic services. We do not give suggestions or recommendations on treatment options.

 

We provide information about potentially suitable treatment options with medicines in development we can find around the globe. Based on that information patients and their doctors decide together if they want to try getting access to such a pre-approval medicine.

 

Book a call with our medical team

 

myTomorrows' Business Model

 

myTomorrows is a business, and to support its mission to provide better access for patients to medicines it does require revenue. When a medicine is reimbursed for a patient, the manufacturer of the medicine pays a fee to myTomorrows for our ongoing regulatory, pharmacovigilance and wholesaler delivery support.

 

In line with the myTomorrows mission of reducing barriers to early access, with many companies myTomorrows agrees to receive reimbursement for today’s early access services in the future, after the medicine has actually been commercialized.

 

 

264.452
264.452
Clinical Trials from global registries in our Knowledge Base
Clinical Trials from global registries in our Knowledge Base
329
329
Early Access Programs
Early Access Programs
175
175
Countries with Early Access Programs / Clinical Trials
Countries with Early Access Programs / Clinical Trials
28m
28m
Scientific publications
Scientific publications

Our Knowledge Base

Our digital healthcare platform contains a Knowledge Base with worldwide information.

 

Be aware that medical information is always complicated. If you need help to understand the information you find, just give us a call. To be sure you get the best results for your specific condition, explained in an easily understandable way, do contact us. 

Search for treatment options

Find treatment options and medical information

      To better refine and understand the results of your search, please contact us, so a member of our medical team can explain your search results, and provide information for you and your doctor to review.

       

      About the founder

       

      myTomorrows was founded in 2012 by Ronald Brus, a doctor who built a career in the pharmaceutical industry, serving as CEO of several large pharmaceutical companies. When his father was diagnosed with lung cancer he experienced firsthand how difficult it was to get access to drugs in development, despite his connections within the industry, knowledge and means.

       

      read more

       

       

      Our Team

       

      Our team is driven, caring, and determined. Many of us have personal experience with serious illness, so we understand the desire to know about all available options when diagnosed with a medical condition.

      While we come from different backgrounds and disciplines, each member of our team contributes expertise...

       

      read more

       

      Proudly backed by